Oct 04, 2024
BeiGene Announces Availability of TEVIMBRA® in U.S.    read more...
Sep 26, 2024
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers    read more...
Sep 26, 2024
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors    read more...
Sep 17, 2024
BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy    read more...
Sep 09, 2024
BeiGene Announces Updates to Commercial Leadership Team    read more...
Sep 09, 2024
BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024    read more...
Aug 28, 2024
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference    read more...
Aug 26, 2024
BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL    read more...
Aug 07, 2024
BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates    read more...
Jul 23, 2024
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World    read more...
Jul 18, 2024
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer    read more...
Jun 14, 2024
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024    read more...
Jun 04, 2024
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference    read more...
May 24, 2024
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL    read more...
May 14, 2024
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024    read more...
May 08, 2024
BeiGene Reports First Quarter 2024 Financial Results and Business Updates    read more...
Apr 26, 2024
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report    read more...
Apr 24, 2024
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting    read more...
Apr 23, 2024
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer    read more...
Mar 14, 2024
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy    read more...